Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
Dupixent might face a threat to its lead in dermatitis – but this comes from Pfizer, not Leo.
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
One trial of Pfizer’s drug in early breast cancer has been stopped, and expectations dim for another.
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.